Bipolar I Disorder Clinical Trial
Official title:
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
Verified date | December 2013 |
Source | University of Cincinnati |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
In this study, quetiapine is being tested for the possible treatment of bipolar I disorder
with an acute depressive episode in children and adolescents.
We hypothesize that quetiapine will be more efficacious than placebo for the treatment of
episodes of major depression associated with adolescent BP. Moreover, we hypothesize that
quetiapine will be safe and well-tolerated compared with placebo for the treatment of
depression associated with adolescent BP. Based on data from the BOLDER study and other
studies of atypical antipsychotics in patients with bipolar depression (Calabrese et al.,
2004, Macfadden et al., 2004, Tohen et al., 2004), which in general reveal effect sizes of
approximately 0.5, a conservative sample size calculation, assuming power of .8, estimates
we would need approximately 15 patients in each group to identify a statistically
significant group difference in our main outcome measure, change form baseline to endpoint
in the Children's Depression Rating Scale (Poznanski, 1979).
Status | Completed |
Enrollment | 30 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 18 Years |
Eligibility |
Inclusion Criteria: To be included in this study, subjects must meet the following criteria: 1. Male or female patients, 12-18 years of age. 2. Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence). 3. Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation. 4. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) BP, type I and currently display an acute depressive episode as determined by K-SADS (Geller et al 2000). 5. Patients must have a baseline (day 0) CDRS score of at least 40. 6. Subjects should be fluent in English. Exclusion Criteria: Patients will be excluded from the protocol for any of the following reasons: 1. Female patients who are either pregnant or lactating. 2. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions. 3. Any history of current or past diabetes that was treated with pharmacological intervention. 4. Neurological disorders including epilepsy, stroke, or severe head trauma. 5. Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, thyroid indices and EKG. 6. Depression due to a general medical condition or substance-induced depression (DSM-IV). 7. Mental retardation (IQ <70). 8. YMRS score of > 12. 9. History of hypersensitivity to or intolerance of quetiapine. 10. Prior history of quetiapine non-response. 11. DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months. 12. Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline CDRS suicide score of > 3). 13. Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry. 14. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0. 15. Treatment with concurrent mood stabilizers or anticonvulsants, benzodiazepines (except as described below), psychostimulants, guanethidine, or guanadrel, or antidepressants. 16. Patient who were treated with carbamazepine at any point during the month prior to screening. 17. Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV. 18. Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified. 19. Subjects who are not fluent in English. |
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
University of Cincinnati | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Children's Depression Rating Scale (CDRS): Measure of efficacy will be a change in CDRS total scores from baseline endpoint. | |||
Secondary | Secondary Efficacy Measures | |||
Secondary | CDRS response rate: Defined by a > 50% decrease from baseline to endpoint in CDRS total score. | |||
Secondary | Clinical Global Impression Improvement Scale BP Version (CGI-I BP) Improvement Score response rate: Defined by an endpoint CGI-I score of 1 or 2 (much or very much improved) | |||
Secondary | Hamilton Anxiety Rating Scale (HAM-A): Measure of efficacy will be change from baseline to endpoint in HAM-A | |||
Secondary | Safety | |||
Secondary | Proportion of patients who met criteria for treatment-emergent mania (YMRS score > 16 on two consecutive visits or at final assessment). | |||
Secondary | Incidence of adverse events | |||
Secondary | Incidence of EPS (as measured by change from baseline to endpoint in EPS rating scales) | |||
Secondary | Change from baseline to endpoint in all laboratory measures and vital signs. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Withdrawn |
NCT01495156 -
Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania
|
Phase 4 | |
Completed |
NCT00982020 -
Study in Adolescents With Schizophrenia or Bipolar Disorder
|
Phase 4 | |
Completed |
NCT00746343 -
Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study
|
N/A | |
Completed |
NCT00177463 -
L-Carnosine for Bipolar I Disorder
|
N/A | |
Completed |
NCT03257865 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
|
Phase 3 | |
Completed |
NCT03259555 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
|
Phase 3 | |
Not yet recruiting |
NCT06433635 -
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
|
Phase 4 | |
Completed |
NCT04127058 -
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
|
Phase 1 | |
Recruiting |
NCT05977023 -
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
|
Phase 2 | |
Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
Completed |
NCT03287869 -
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
|
Phase 3 | |
Enrolling by invitation |
NCT04987229 -
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
Completed |
NCT03292848 -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
|
Phase 1 | |
Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
Recruiting |
NCT03943537 -
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
|
Phase 2 | |
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Completed |
NCT00958633 -
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
|
Phase 3 |